{"transactions":[{"id":2672,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2671,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2670,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":175345,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":175345},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2669,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":158371,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":703469,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-25T00:00:20.000Z","date":"2026-07-24","kind":"gift","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":158371,"source":{"system":"sec-edgar","filing":"0001104659-26-086729","document":"tm2621304-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926086729/tm2621304-1_4seq1.xml","form_type":"4"}},{"id":793702,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":289,"price":83.16,"value":24033.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":173371,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":793701,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":82.6,"value":74340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":173660,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":793700,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":811,"price":81.02,"value":65707.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":174560,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":805516,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-18T00:00:15.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":90,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."}],"balance_after":175371,"source":{"system":"sec-edgar","filing":"0001104659-26-045062","document":"tm2612090-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926045062/tm2612090-1_4seq1.xml","form_type":"4"}},{"id":816117,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:08.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":85.46,"value":94006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.17 to $85.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":177371,"source":{"system":"sec-edgar","filing":"0001104659-26-039708","document":"tm2611042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926039708/tm2611042-2_4seq1.xml","form_type":"4"}},{"id":816116,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:08.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":84.46,"value":76014.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.15 to $85.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":178471,"source":{"system":"sec-edgar","filing":"0001104659-26-039708","document":"tm2611042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926039708/tm2611042-2_4seq1.xml","form_type":"4"}},{"id":826289,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-28T00:00:19.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":85,"value":170000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."}],"balance_after":179371,"source":{"system":"sec-edgar","filing":"0001104659-26-036332","document":"tm269945-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926036332/tm269945-1_4seq1.xml","form_type":"4"}},{"id":861252,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T01:00:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":406,"price":71.66,"value":29093.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.04 to $71.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":181371,"source":{"system":"sec-edgar","filing":"0001104659-26-023651","document":"tm267888-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926023651/tm267888-1_4seq1.xml","form_type":"4"}},{"id":861251,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T01:00:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":994,"price":70.45,"value":70027.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":181777,"source":{"system":"sec-edgar","filing":"0001104659-26-023651","document":"tm267888-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926023651/tm267888-1_4seq1.xml","form_type":"4"}},{"id":861250,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T01:00:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":300,"price":69.43,"value":20829.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.91 to $69.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":182771,"source":{"system":"sec-edgar","filing":"0001104659-26-023651","document":"tm267888-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926023651/tm267888-1_4seq1.xml","form_type":"4"}},{"id":861249,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-05T01:00:25.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":300,"price":68.27,"value":20481.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.77 to $68.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":183071,"source":{"system":"sec-edgar","filing":"0001104659-26-023651","document":"tm267888-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926023651/tm267888-1_4seq1.xml","form_type":"4"}},{"id":919291,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:01:01.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":66.89,"value":6689.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."}],"balance_after":183371,"source":{"system":"sec-edgar","filing":"0001104659-26-010453","document":"tm265045-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926010453/tm265045-1_4seq1.xml","form_type":"4"}},{"id":919290,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:01:01.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":1108,"price":66.15,"value":73294.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.84 to $66.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":183471,"source":{"system":"sec-edgar","filing":"0001104659-26-010453","document":"tm265045-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926010453/tm265045-1_4seq1.xml","form_type":"4"}},{"id":919289,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:01:01.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":792,"price":65.21,"value":51646.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":184579,"source":{"system":"sec-edgar","filing":"0001104659-26-010453","document":"tm265045-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926010453/tm265045-1_4seq1.xml","form_type":"4"}},{"id":946220,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:42.000Z","date":"2026-01-02","kind":"grant","planned":true,"acquired":true,"shares":83690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":83690,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001104659-26-001483","document":"tm261906-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926001483/tm261906-1_4seq1.xml","form_type":"4"}},{"id":946219,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:00:42.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":80,"value":160000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":185371,"source":{"system":"sec-edgar","filing":"0001104659-26-001483","document":"tm261906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926001483/tm261906-1_4seq1.xml","form_type":"4"}},{"id":946218,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:00:42.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":4080,"price":75.2,"value":306816.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":187371,"source":{"system":"sec-edgar","filing":"0001104659-26-001483","document":"tm261906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926001483/tm261906-1_4seq1.xml","form_type":"4"}},{"id":946217,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-07T01:00:42.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":1920,"price":74.13,"value":142329.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.67 to $74.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":191451,"source":{"system":"sec-edgar","filing":"0001104659-26-001483","document":"tm261906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926001483/tm261906-1_4seq1.xml","form_type":"4"}},{"id":959506,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-24T01:00:22.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":80,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":193371,"source":{"system":"sec-edgar","filing":"0001104659-25-124354","document":"tm2534063-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465925124354/tm2534063-1_4seq1.xml","form_type":"4"}},{"id":976139,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.009,"expiration_date":"2029-04-03","underlying":"Common Stock","underlying_shares":11797},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976138,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976137,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976136,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976135,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976134,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-08","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":976133,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:06:19.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer (\"Company Common Stock\") upon vesting of the Company RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312098","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312098/ownership.xml","form_type":"4"}},{"id":978907,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-06T01:02:10.000Z","date":"2025-12-04","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":75,"value":112500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":194871,"source":{"system":"sec-edgar","filing":"0001104659-25-118985","document":"tm2532835-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465925118985/tm2532835-2_4seq1.xml","form_type":"4"}},{"id":986144,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-29T01:00:22.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":70,"value":105000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":196371,"source":{"system":"sec-edgar","filing":"0001104659-25-117036","document":"tm2532308-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465925117036/tm2532308-1_4seq1.xml","form_type":"4"}},{"id":998807,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-15T01:00:20.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":65,"value":130000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":197871,"source":{"system":"sec-edgar","filing":"0001104659-25-112825","document":"tm2531402-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465925112825/tm2531402-1_4seq1.xml","form_type":"4"}},{"id":1000094,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-14T01:37:12.000Z","date":"2025-11-11","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":60,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024."}],"balance_after":199871,"source":{"system":"sec-edgar","filing":"0001104659-25-111631","document":"tm2531086-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465925111631/tm2531086-1_4seq1.xml","form_type":"4"}},{"id":1061694,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-19T20:42:18.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000161071725000301/form4.xml","form_type":"4"}},{"id":1068972,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-12T20:32:47.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are vested and currently exercisable."}],"balance_after":11797,"derivative":{"exercise_price":7.009,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000950170-25-107545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025107545/ownership.xml","form_type":"4"}},{"id":1068971,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T20:32:47.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":47.457,"value":142371.0,"ownership":{"direct":true},"balance_after":9398,"source":{"system":"sec-edgar","filing":"0000950170-25-107545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025107545/ownership.xml","form_type":"4"}},{"id":1068970,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T20:32:47.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":7.009,"value":21027.0,"ownership":{"direct":true},"balance_after":12398,"source":{"system":"sec-edgar","filing":"0000950170-25-107545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025107545/ownership.xml","form_type":"4"}},{"id":1104909,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T21:39:01.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000244","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000161071725000244/form4.xml","form_type":"4"}},{"id":1121428,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T16:07:09.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":9398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":9398,"source":{"system":"sec-edgar","filing":"0000950170-25-082311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025082311/ownership.xml","form_type":"4"}},{"id":1335385,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-12T01:02:27.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":124962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 124,962 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":124962,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001104659-24-127705","document":"tm2430773-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465924127705/tm2430773-2_4seq1.xml","form_type":"4"}},{"id":1424166,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-24T00:05:04.000Z","date":"2024-08-23","kind":"sale","planned":false,"acquired":false,"shares":6000,"price":48.26,"value":289560.0,"ownership":{"direct":true},"balance_after":200871,"source":{"system":"sec-edgar","filing":"0001104659-24-092519","document":"tm2422592-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465924092519/tm2422592-1_4seq1.xml","form_type":"4"}},{"id":1483549,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T17:24:20.000Z","date":"2024-06-08","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":26000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-072066","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024072066/ownership.xml","form_type":"4"}},{"id":1488275,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:26:50.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":39402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary measured from June 4, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":39402,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":39402},"source":{"system":"sec-edgar","filing":"0001610717-24-000297","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000161071724000297/form4.xml","form_type":"4"}},{"id":1488274,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:26:50.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":19785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the \"Vesting Commencement Date\") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":19785,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":19785},"source":{"system":"sec-edgar","filing":"0001610717-24-000297","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000161071724000297/form4.xml","form_type":"4"}},{"id":1703267,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-21T01:00:47.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":175345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":175345,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":175345},"source":{"system":"sec-edgar","filing":"0001104659-23-127820","document":"tm2333399-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923127820/tm2333399-2_4seq1.xml","form_type":"4"}},{"id":1830239,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.94,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":23186},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830238,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.82,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830237,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.14,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830236,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.39,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830235,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.775,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830234,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.85,"expiration_date":"2028-01-12","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830233,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1830232,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-13T17:57:14.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 11, 2023, pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated April 28, 2023, by and among IVERIC bio, Inc. (\"IVERIC\"), Astellas US Holding, Inc., Berry Merger Sub, Inc. (\"Merger Sub\") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. (\"Astellas\"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of IVERIC common stock (\"Common Stock\") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-080683","document":"tm2321002-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465923080683/tm2321002-4_4seq1.xml","form_type":"4"}},{"id":1843496,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-27T17:55:10.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-23-030220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023030220/ownership.xml","form_type":"4"}},{"id":1847908,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T17:47:10.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are vested and currently exercisable."}],"balance_after":14797,"derivative":{"exercise_price":7.01,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-23-029228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023029228/ownership.xml","form_type":"4"}},{"id":1847907,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T17:47:10.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":22498,"price":54.4622,"value":1225290.5756,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.20 to $55.135, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-029228","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023029228/ownership.xml","form_type":"4"}},{"id":1847906,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T17:47:10.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":17502,"price":53.7878,"value":941394.0756,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.20 to $54.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":22498,"source":{"system":"sec-edgar","filing":"0000950170-23-029228","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023029228/ownership.xml","form_type":"4"}},{"id":1847905,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T17:47:10.000Z","date":"2023-06-16","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":7.01,"value":280400.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0000950170-23-029228","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023029228/ownership.xml","form_type":"4"}},{"id":1884416,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-19T21:49:58.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001410939-23-000082","document":"wk-form4_1684532980.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093923000082/wk-form4_1684532980.xml","form_type":"4"}},{"id":1893383,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-15T20:47:22.000Z","date":"2023-05-11","kind":"exercise","planned":false,"acquired":false,"shares":14588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 of the Registrant's restricted stock units on May 12, 2022. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units vested in full one business day prior to the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14588},"source":{"system":"sec-edgar","filing":"0001410939-23-000073","document":"wk-form4_1684183629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093923000073/wk-form4_1684183629.xml","form_type":"4"}},{"id":1893382,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-15T20:47:22.000Z","date":"2023-05-11","kind":"exercise","planned":false,"acquired":true,"shares":14588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":22088,"source":{"system":"sec-edgar","filing":"0001410939-23-000073","document":"wk-form4_1684183629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093923000073/wk-form4_1684183629.xml","form_type":"4"}},{"id":2244916,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:06:36.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020942","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322020942/doc4.xml","form_type":"4"}},{"id":2271852,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-13T22:07:08.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":23186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted a stock option to purchase 23,186 shares of the Registrant's common stock. Subject to the Reporting Person providing continued services to the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":23186,"derivative":{"exercise_price":9.94,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":23186},"source":{"system":"sec-edgar","filing":"0001410939-22-000070","document":"wf-form4_165247958227090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093922000070/wf-form4_165247958227090.xml","form_type":"4"}},{"id":2271851,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-13T22:07:08.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":14588,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with the Registrant's Non-Employee Director Compensation Policy, the Reporting Person was granted 14,588 restricted stock units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2023 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":14588,"derivative":{"underlying":"Common Stock","underlying_shares":14588},"source":{"system":"sec-edgar","filing":"0001410939-22-000070","document":"wf-form4_165247958227090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093922000070/wf-form4_165247958227090.xml","form_type":"4"}},{"id":2271850,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-13T22:07:08.000Z","date":"2022-05-11","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 19, 2021, the Reporting Person was granted 7,500 restricted stock units, which vest in full upon on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001410939-22-000070","document":"wf-form4_165247958227090.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093922000070/wf-form4_165247958227090.xml","form_type":"4"}},{"id":2271849,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T22:07:08.000Z","date":"2022-05-11","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001410939-22-000070","document":"wf-form4_165247958227090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000141093922000070/wf-form4_165247958227090.xml","form_type":"4"}},{"id":2419144,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T23:15:40.000Z","date":"2022-01-30","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four-year period measured from one month following January 30, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date."}],"balance_after":175000,"derivative":{"exercise_price":6.78,"expiration_date":"2032-01-29","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-22-006024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000120919122006024/doc4.xml","form_type":"4"}},{"id":2683498,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:58:02.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076500","document":"tm2118278-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076500/tm2118278-6_4seq1.xml","form_type":"4"}},{"id":2702940,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-05-20T23:54:20.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-21-070100","document":"tm2117174-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465921070100/tm2117174-4_4seq1.xml","form_type":"4"}},{"id":2702939,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T23:54:20.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest monthly with respect to 1/12 of the shares underlying such stock option award until the earlier of the business day immediately prior to the Registrant's 2022 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the stock option award will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2013 Stock Incentive Plan)."}],"balance_after":15500,"derivative":{"exercise_price":6.82,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001104659-21-070100","document":"tm2117174-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465921070100/tm2117174-4_4seq1.xml","form_type":"4"}},{"id":2720851,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-05-10T20:45:34.000Z","date":"2021-05-03","kind":"grant","acquired":true,"shares":92500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis."}],"balance_after":92500,"derivative":{"exercise_price":2.79,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":92500},"source":{"system":"sec-edgar","filing":"0001485003-21-000110","document":"wf-form4_162069392081695.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000110/wf-form4_162069392081695.xml","form_type":"4"}},{"id":3113269,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T18:01:32.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Registrant's 2021 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":4.14,"underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-20-072339","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465920072339/a4.xml","form_type":"4"}},{"id":3127265,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T18:54:50.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":25.2,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-20-069077","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920069077/a4.xml","form_type":"4"}},{"id":3156385,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-05-08T17:49:56.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 6, 2020 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested."}],"balance_after":59000,"derivative":{"exercise_price":0.6294,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001485003-20-000054","document":"wf-form4_158897457961477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500320000054/wf-form4_158897457961477.xml","form_type":"4"}},{"id":3481394,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-06-21T16:12:51.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 19, 2019 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested."}],"balance_after":52500,"derivative":{"exercise_price":1.48,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001485003-19-000040","document":"wf-form4_156114795621041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500319000040/wf-form4_156114795621041.xml","form_type":"4"}},{"id":3523709,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:13:29.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Issuer's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2020 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":1.39,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-19-030032","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465919030032/a4.xml","form_type":"4"}},{"id":3869246,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-11T20:47:08.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to Reporting Person providing continued services to the Issuer and other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the option will vest and become exercisable in 12 consecutive, equal installments on each consecutive monthly anniversary of the date of grant, until fully vested and exercisable on the first anniversary of the date of grant. Any unvested shares subject to the option will be accelerated in full one business day prior to the Issuer's 2019 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":2.775,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-18-044689","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465918044689/a4.xml","form_type":"4"}},{"id":3893889,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-06-14T16:08:44.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 12, 2018 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested."}],"balance_after":52500,"derivative":{"exercise_price":2.24,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001485003-18-000091","document":"wf-form4_152900690635319.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500318000091/wf-form4_152900690635319.xml","form_type":"4"}},{"id":3983048,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-23","kind":"exercise","acquired":false,"shares":11200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":165584,"derivative":{"exercise_price":11.97,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":11200},"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3983047,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-22","kind":"exercise","acquired":false,"shares":19900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":176784,"derivative":{"exercise_price":11.97,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":19900},"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3983046,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-23","kind":"sale","acquired":false,"shares":11200,"price":20.52,"value":229824.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3983045,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-23","kind":"exercise","acquired":true,"shares":11200,"price":11.97,"value":134064.0,"ownership":{"direct":true},"balance_after":11200,"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3983044,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-22","kind":"sale","acquired":false,"shares":19900,"price":21.07,"value":419293.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3983043,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-26T20:02:25.000Z","date":"2018-03-22","kind":"exercise","acquired":true,"shares":19900,"price":11.97,"value":238203.0,"ownership":{"direct":true},"balance_after":19900,"source":{"system":"sec-edgar","filing":"0001104659-18-020100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/a4.xml","form_type":"4"}},{"id":3987669,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-19","kind":"exercise","acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan.  The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":196684,"derivative":{"exercise_price":11.97,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":3987668,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-16","kind":"exercise","acquired":false,"shares":15416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan.  The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service."}],"balance_after":198584,"derivative":{"exercise_price":11.97,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":15416},"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":3987667,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":1900,"price":21.76,"value":41344.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $21.80, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":3987666,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-19","kind":"exercise","acquired":true,"shares":1900,"price":11.97,"value":22743.0,"ownership":{"direct":true},"balance_after":1900,"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":3987665,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-16","kind":"sale","acquired":false,"shares":15416,"price":22.15,"value":341464.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.42, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":3987664,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & SVP, Corp. Dev."}}],"security":"Common Stock","published_at":"2018-03-20T21:43:31.000Z","date":"2018-03-16","kind":"exercise","acquired":true,"shares":15416,"price":11.97,"value":184529.52,"ownership":{"direct":true},"balance_after":15416,"source":{"system":"sec-edgar","filing":"0001104659-18-019018","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/a4.xml","form_type":"4"}},{"id":4003444,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-10T00:11:19.000Z","date":"2018-03-07","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan.  The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date.  The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":65000,"derivative":{"exercise_price":28.72,"expiration_date":"2028-03-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001104659-18-016413","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918016413/a4.xml","form_type":"4"}},{"id":4097749,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-17T22:06:06.000Z","date":"2018-01-13","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting commencement date (\"Vesting Commencement Date\") of the option is January 13, 2018. The option vests with respect to one-thirty sixth (1/36th) of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":32000,"derivative":{"exercise_price":2.85,"expiration_date":"2028-01-12","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-18-002660","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465918002660/a4.xml","form_type":"4"}},{"id":4308137,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-05-23T16:43:00.000Z","date":"2017-05-19","kind":"grant","acquired":true,"shares":8072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested."}],"balance_after":8072,"derivative":{"exercise_price":1.48,"expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":8072},"source":{"system":"sec-edgar","filing":"0001485003-17-000065","document":"wf-form4_149557216490440.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500317000065/wf-form4_149557216490440.xml","form_type":"4"}},{"id":4498713,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P. & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T22:26:55.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":214000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. 53,500 of the shares of common stock underlying the options will vest on 1/1/2018 and the remainder will vest in 36 equal monthly installments thereafter, subject to continued service."}],"balance_after":214000,"derivative":{"exercise_price":11.97,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":214000},"source":{"system":"sec-edgar","filing":"0001104659-17-000985","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465917000985/a4.xml","form_type":"4"}}]}